Wells Fargo & Company Cardiol Therapeutics Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 2,000 shares of CRDL stock, worth $2,300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,000
Previous 2,000
-0.0%
Holding current value
$2,300
Previous $3,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CRDL
# of Institutions
46Shares Held
7.58MCall Options Held
4.9KPut Options Held
3.8K-
Tejara Capital LTD London, X03.12MShares$3.58 Million2.61% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD882KShares$1.01 Million0.23% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9796KShares$914,9680.31% of portfolio
-
Pvg Asset Management Corp Golden, CO487KShares$560,3893.54% of portfolio
-
Cambridge Investment Research Advisors, Inc.331KShares$380,0800.0% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $71.2M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...